Peer-reviewed veterinary case report
Toll-like receptor-5 drug tested for radiation mouth sores in beagle
By Ko, Jaeeun et al.·Published in Frontiers in veterinary science·2022·Department of Veterinary Medical Imaging, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical evaluation of toll-like receptor-5 agonist for radiation-induced oral mucositis in beagle dogs.
- Species:
- dog
Plain-English summary
A group of beagle dogs developed painful sores in their mouths after receiving radiation treatment, which is known as oral mucositis. Researchers tested a drug called KMRC011 to see if it could help reduce the severity of these sores. While all the dogs experienced some level of mucositis, those treated with KMRC011 had less redness and fewer ulcers compared to those who did not receive the drug. The treatment appeared to be safe, with no severe side effects noted, suggesting that KMRC011 could be a helpful option for dogs undergoing radiation therapy.
People also search for: beagle dog mouth sores treatment · radiation side effects in dogs · KMRC011 for oral mucositis in dogs
Abstract
This study aimed to evaluate the clinical safety and validate the radiomitigative effect of KMRC011, against radiation-induced oral mucositis in beagle dogs. Clinical safety was evaluated by assessing tolerability, complete blood tests, and plasma biochemistry after drug administration. The radiomitigative effect of KMRC011 was evaluated macropathologically and histopathologically after inducing oral mucositis iatrogenically using 20 Gy irradiation. The plasma concentration of interleukin-6 was measuredenzyme-linked immunosorbent assay, as a biomarker of KMRC011 bioreactivity. Decreased tolerability, increased neutrophil count, hepatic enzyme concentration, C-reactive protein concentration, and interleukin-6 concentration after the administration was observed and ceased within 24 h without additional treatment. Although all animals included in the present study developed severe mucositis in the late course of the study, animals administered KMRC011 showed less erythema, ulcer, inflammatory infiltration. These results suggest that KMRC011 may be used as an adjuvant for radiotherapy without severe adverse effects, especially during short-term radiotherapy, such as hypofractionated radiotherapy or stereotactic radiotherapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36032288/